Discussing Novel and Emerging Monoclonal Antibody Therapies for Treatment of Age-Related Macular Degeneration and Diabetic Macular Edema

Add-on activity

This activity includes animation videos.

Program Description

Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are serious effects of diabetic retinopathy that patients can experience. The pathways for these disease states are based primarily around angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A). These factors can cause inflammation, leakage, discomfort, and vision impairment for patients. The first-line treatment for nAMD and DME is monotherapy with an anti-VEGF agent. This treatment conveys a heavy burden on both patients and providers, with frequent scheduled injections and patient monitoring required. Pharmacists can contribute to the care management of patients with nAMD and DME by becoming familiar with emerging therapies that have a unique dual mechanism. These therapies have the potential to improve outcomes as well as reduce treatment burden for the patient. This panel discussion led by experts will inform managed care professionals about current treatment guidelines as well as present evidence for the role of emerging therapies in the improvement of outcomes for patients with nAMD and DME.

Target audience: Health-system and managed care pharmacists

Type of activity: Application
Release date: April 22, 2022
Expiration date: April 22, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the impact of current treatment options for age-related macular degeneration (AMD) and diabetic macular edema (DME) on patient quality of life, highlighting challenges and barriers that may impact outcomes
• Determine how advances in new dual mechanism therapeutic options can impact treatment for neovascular AMD/DME and discuss mechanism of action, efficacy, and safety data
• Identify how managed care professionals can address barriers to treatment for patients with AMD and DME

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-187-H01-P. The activity is available for CE credit through April 22, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Arghavan Almony, MD, has the following financial relationship with a commercial interest to disclose:
Consultant: Cardinal Health

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Erica Marini, PharmD, MS, BCPS
Douglas S. Burgoyne, PharmD, FAMCP
Natalie M. Ryan, PharmD, BCPP, CSP, MS

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle Carlson, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms